Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populations

Basit Öğe Kaydı
dc.contributor.authorÇelik, Önder
dc.contributor.authorÇelik, Nilüfer
dc.contributor.authorAydın, Süleyman
dc.contributor.authorBaysal, Bora
dc.contributor.authorAydın, Suna
dc.contributor.authorSa?lam, Aylin
dc.contributor.authorGürsu, Yağmur
dc.contributor.authorDalkılıç, Semih
dc.contributor.authorUlaş, Mustafa
dc.contributor.authorÖzçil, Mustafa Doğan
dc.contributor.authorTayyar, Ahter Tanay
dc.contributor.authorCengiz, Ferhat
dc.contributor.authorUğur, Kader
dc.contributor.authorAkkoç, Ramazan Fazıl
dc.contributor.authorErşahin, Aynur Adeviye
dc.date.accessioned2020-09-24T05:53:21Z
dc.date.available2020-09-24T05:53:21Z
dc.date.issued2020
dc.departmentTıp Fakültesi
dc.descriptionSa?lam, Aylin ( Aksaray, Yazar )
dc.description.abstractIt can be misleading to think that the new severe acute respiratory syndrome coronavirus (SARS-CoV2) which has a very strong mutation and adaptation capabilities, uses only the angiotensin-converting enzyme II (ACE2) pathway to reach target cells. Despite all the precautions taken, the pandemic attack continues and the rapid increase in the number of deaths suggest that this virus has entered the cell through different pathways and caused damage through different mechanisms. The main reason why the ACE2 pathway comes to the fore in all scientific studies is that this receptor is located at the entry point of basic mechanisms that provide alveolo-capillary homeostasis. SARS-CoV-2 has to use nuclear factor-?B (NF-kB), caveloae, clathrin, lipoxin, serine protease and proteasome pathways in addition to ACE2 to enter the target cell and initiate damage. For this reason, while new drug development studies are continuing, in order to be beneficial to patients in their acute period, it is imperative that we are able to come up with drugs that activate or inhibit these pathways and are currently in clinical use. It is also critical that we adopt these new pathways to the treatment of pregnant women affected by SARS-CoV-2, based on the scientific data we use to treat the general population.
dc.identifier.doi10.14715/cmb/2020.66.3.36
dc.identifier.endpage229en_US
dc.identifier.issn1165-158X
dc.identifier.issue3en_US
dc.identifier.pmid32538775
dc.identifier.scopusqualityQ4
dc.identifier.startpage221en_US
dc.identifier.urihttps:/dx.doi.org/10.14715/cmb/2020.66.3.36
dc.identifier.urihttps://hdl.handle.net/20.500.12451/7680
dc.identifier.volume66en_US
dc.identifier.wosWOS:000540410000036
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofCellular and molecular biology (Noisy-le-Grand, France)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectACE2
dc.subjectNuclear Factor-?B
dc.subjectOff Label Drugs
dc.subjectProteasome
dc.subjectSARS-CoV-2
dc.subjectSerine Protease
dc.subjectViral Entry Pathways
dc.titleCombating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populations
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu